Format

Send to

Choose Destination
Semin Cutan Med Surg. 2014 Jun;33(3 Suppl):S57-9. doi: 10.12788/j.sder.0094.

Current and emerging nonsurgical treatment options for hidradenitis suppurativa.

Author information

1
Director of Inpatient Dermatology, University of Miami Hospital; Professor of Dermatology and Vice Chairman, Florida International University, Miami, FL.

Abstract

Several nonsurgical strategies for managing hidradenitis suppurativa (HS) are used that are successful in many patients. The overall goals of pharmacologic therapy are to clear or reduce the number and extent of current lesions and to prevent new lesions from forming. No pharmacologic agent is universally effective in all patients with HS, and, to date, none has been approved for this indication by the US Food and Drug Administration. Among the agents most commonly used are topical and systemic antibiotics and intralesional and systemic corticosteroids. Within the past decade, clinical experience with biologic agents-principally, tumor necrosis factor inhibitors-has been described, and the results of clinical trials with these agents in patients with HS have been promising.

KEYWORDS:

adalimumab; antibiotics; biologic agents; corticosteroids; hidradenitis suppurativa; infliximab; tumor necrosis factor inhibitors

PMID:
25188460
DOI:
10.12788/j.sder.0094
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Frontline Medical Communications Inc
Loading ...
Support Center